Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Fresh from the Pipeline
  • Published:

Tolvaptan

Nature Reviews Drug Discovery volume 8, pages 611–612 (2009)Cite this article

Abstract

In May 2009, tolvaptan (Samsca; Otsuka), a selective vasopressin V2 receptor antagonist, was approved by the US FDA for the treatment of clinically significant hypervolaemic and euvolaemic hyponatraemia.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Figure 1: Tolvaptan.

References

  1. Ghali, J. K. Mechanisms, risks, and new treatment options for hyponatremia. Cardiology 111, 147–157 (2008).

    Article  CAS  PubMed  Google Scholar 

  2. Chen, S. et al. Evaluation and management of hyponatremia: an emerging role for vasopressin receptor antagonists. Nature Clin. Pract. Nephrol. 3, 82–95 (2007).

    Article  CAS  Google Scholar 

  3. Ali, F. et al. Therapeutic potential of vasopressin receptor antagonists. Drugs 67, 847–858 (2007).

    Article  CAS  PubMed  Google Scholar 

  4. Yamamura, Y. et al. OPC-41061, a highly potent human vasopressin V2-receptor antagonist: pharmacological profile and aquaretic effect by single and multiple oral dosing in rats. J. Pharmacol. Exp. Ther. 287, 860–867 (1998).

    CAS  PubMed  Google Scholar 

  5. Kondo, K. et al. 7-Chloro-5-hydroxy-1-[2-methyl-4-(2-methylbenzoyl-amino)benzoyl]-2,3,4,5-tetrahydro-1H-1-benzazepine (OPC-41061): a potent, orally active nonpeptide arginine vasopressin V2 receptor antagonist. Bioorg. Med. Chem. 7, 1743–1754 (1999).

    Article  CAS  PubMed  Google Scholar 

  6. Miyazaki, T. et al.Therapeutic effects of tolvaptan, a potent, selective nonpeptide vasopressin V2 receptor antagonist, in rats with acute and chronic severe hyponatremia. Endocrinology 146, 3037–3043 (2005).

    Article  CAS  PubMed  Google Scholar 

  7. Food and Drug Administration. FDA labelling information. FDA web site [online], (2009).

  8. Schrier, R. W. et al. Tolvaptan, a selective oral vasopressin V2-receptor antagonist, for hyponatremia. N. Engl. J. Med. 355, 2099–2112 (2006).

    Article  CAS  PubMed  Google Scholar 

  9. Konstam, M. A. et al. Effects of oral tolvaptan in patients hospitalized for worsening heart failure: the EVEREST Outcome Trial. JAMA 297, 1319–1331 (2007).

    Article  CAS  PubMed  Google Scholar 

  10. Ali, F. et al. Conivaptan: a dual vasopressin receptor V1A/V2 antagonist. Cardiovascular Drug Rev. 25, 261–279 (2007).

    Article  CAS  Google Scholar 

  11. Udelson, J. E. et al. Multicenter, randomized, double-blind, placebo-controlled study on the effect of oral tolvaptan on left ventricular dilation and function inpatient with heart failure and systolic dysfunction. J. Am. Coll. Cardiol. 49, 2151–2159 (2007).

    Article  CAS  PubMed  Google Scholar 

  12. IMS MIDAS MAT Q4 (IMS Health, 2008).

Download references

Author information

Authors and Affiliations

  1. Jalal K. Ghali is at Harper University Hospital, 3990 John R Street, 9 Webber Core, Detroit, Michigan 48201, USA.,

    Jalal K. Ghali

  2. Bashar Hamad and Uma Yasothan are at IMS Health, 7 Harewood Avenue, London, NW1 6JB, UK.,

    Bashar Hamad & Uma Yasothan

  3. Peter Kirkpatrick is at Nature Reviews Drug Discovery. JGhali@dmc.org bhamad@uk.imshealth.com p.kirkpatrick@nature.com,

    Peter Kirkpatrick

Authors
  1. Jalal K. Ghali
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Bashar Hamad
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Uma Yasothan
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Peter Kirkpatrick
    View author publications

    You can also search for this author in PubMed Google Scholar

Ethics declarations

Competing interests

J.K.G. is a consultant for Astellas and Otsuka, and has received research grants from CardioKine Inc. and Biogen Idec.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Ghali, J., Hamad, B., Yasothan, U. et al. Tolvaptan. Nat Rev Drug Discov 8, 611–612 (2009). https://doi.org/10.1038/nrd2946

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1038/nrd2946

This article is cited by

Search

Advanced search

Quick links

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing